Ticker	Volume	Price	Price Delta
DJIA	15,387.60	+52.30	0.34%
S&P 500	1,669.16	+2.87	0.17%
Nasdaq	3,502.12	+5.69	0.16%

Ticker

Volume

Price

Price Delta

DJIA

15,387.60

+52.30

0.34%

S&P 500

1,669.16

+2.87

0.17%

Nasdaq

3,502.12

+5.69

0.16%

Ticker	Volume	Price	Price Delta
STOXX 50	2,821.65	-2.85	-0.10%
FTSE 100	6,803.87	+48.24	0.71%
DAX	8,472.20	+16.37	0.19%

Ticker

Volume

Price

Price Delta

STOXX 50

2,821.65

-2.85

-0.10%

FTSE 100

6,803.87

+48.24

0.71%

DAX

8,472.20

+16.37

0.19%

Ticker	Volume	Price	Price Delta
Nikkei	15,381.00	+20.21	0.13%
Hang Seng	23,366.40	-126.66	-0.54%
S&P/ASX 200	5,180.06	-28.98	-0.56%

Ticker

Volume

Price

Price Delta

Nikkei

15,381.00

+20.21

0.13%

Hang Seng

23,366.40

-126.66

-0.54%

S&P/ASX 200

5,180.06

-28.98

-0.56%

Medivation Shares Almost Double in Early Trading on Positive Drug Result

By Bruce Rule - 2011-11-03T11:42:44Z

Medivation Inc. (MDVN) almost doubled in early trading after saying that a trial of the company’s prostate cancer drug has been halted and the medicine will be given to all participants.

Medivation surged to $32 at 7:33 a.m. The trial’s monitoring committee made the recommendation after seeing interim results, the San Francisco-based company and partner Astellas Pharma Inc. (4503) said in a statement today.

To contact the reporter on this story: Bruce Rule in New York at brule1@bloomberg.net

To contact the editor responsible for this story: Bruce Rule at brule1@bloomberg.net

More News:

Health Care

Bloomberg moderates all comments. Comments that are abusive or off-topic will not be posted to the site. Excessively long comments may be moderated as well. Bloomberg cannot facilitate requests to remove comments or explain individual moderation decisions.